결핵 진료지침
66. Ramachandran G, Hemanth Kumar AK, Srinivasan R, Geetharani A, Sugirda P, Nandhakumar B, et al. Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. Indian J Med Res 2012;136:979-84.
67. Vogensen VB, Bolhuis MS, Sturkenboom MGG, van der Werf TS, de Lange WCM, Anthony RM, et al. Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid-resistant/intolerant tuberculosis patients. Antimicrob Agents Chemother 2022;66:e0182921.
68. Global tuberculosis report 2022. Geneva: World Health Organization; 2022.
69. 질병관리청. 2022 결핵환자 신고현황 연보
70. Choi H, Mok J, Kang YA, Jeong D, Kang HY, Kim HJ, et al. Nationwide treatment outcomes of patients with multidrug/rifampin-resistant tuberculosis in Korea, 2011-2017: A retrospective cohort study (Korean TB-POST). J Korean Med Sci 2023;38:e33.
71. Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet 2022; 400:1858–68.
72. Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet 2022;400:1522–30.
73. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2022.
74. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979;76(6 Suppl):771–81.
75. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1980;1:231–41.
76. Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL, et al. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. Int J Tuberc Lung Dis 2018;22:239–45.
77. Caminero JA, García-Basteiro AL, Rendon A. Multidrug-resistant tuberculosis. Lancet 2019;394:298.
78. Choi H, Jeong D, Kang YA, Jeon D, Kang HY, Kim HJ, et al. Impact of anti-tuberculosis drug use on treatment outcomes in patients with pulmonary fluoroquinolone-resistant multidrug-resistant tuberculosis: A nationwide retrospective cohort study with propensity score matching. Tuberc Respir Dis (Seoul) 2023;86:234–44.
79. 질병관리청. 국가결핵관리지침 2022.
80. Lee T, Lee SJ, Jeon D, Lee HY, Kim HJ, Kang BH, et al. Additional drug resistance in patients with multidrug-resistant tuberculosis in Korea: a multicenter study from 2010 to 2019. J Korean Med Sci 2021;36:e174.
81. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019.
82. 결핵 진료지침 개정위원회. 결핵 진료지침 4판. 2020.
83. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. Geneva: World Health Organization; 2016.
84. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.
85. Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al. Bedaquiline, delamanid, linezolid and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis 2022; 76:e938–e46.
86. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393–400.
<PAGE>140
Ⅲ. 약제내성결핵의 치료